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Background: SARS-CoV-2 serology is used to identify prior infection at individual and at population level.
Extended longitudinal studies with multi-timepoint sampling to evaluate dynamic changes in antibody lev-
els are required to identify the time horizon in which these applications of serology are valid, and to explore
the longevity of protective humoral immunity.
Methods: Healthcare workers were recruited to a prospective cohort study from the first SARS-CoV-2 epi-
demic peak in London, undergoing weekly symptom screen, viral PCR and blood sampling over 1621
weeks. Serological analysis (n =12,990) was performed using semi-quantitative Euroimmun IgG to viral spike
S1 domain and Roche total antibody to viral nucleocapsid protein (NP) assays. Comparisons were made to
pseudovirus neutralizing antibody measurements.
Findings: A total of 157/729 (21.5%) participants developed positive SARS-CoV-2 serology by one or other
assay, of whom 31.0% were asymptomatic and there were no deaths. Peak Euroimmun anti-S1 and Roche
anti-NP measurements correlated (r = 0.57, p<0.0001) but only anti-S1 measurements correlated with near-
contemporary pseudovirus neutralising antibody titres (measured at 1618 weeks, r = 0.57, p<0.0001). By
21 weeks’ follow-up, 31/143 (21.7%) anti-S1 and 6/150 (4.0%) anti-NP measurements reverted to negative.
Mathematical modelling revealed faster clearance of anti-S1 compared to anti-NP (median half-life of 2.5
weeks versus 4.0 weeks), earlier transition to lower levels of antibody production (median of 8 versus 13
weeks), and greater reductions in relative antibody production rate after the transition (median of 35% versus
50%).
Interpretation: Mild SARS-CoV-2 infection is associated with heterogeneous serological responses in Euroim-
mun anti-S1 and Roche anti-NP assays. Anti-S1 responses showed faster rates of clearance, more rapid transi-
tion from high to low level production rate and greater reduction in production rate after this transition. InKeywords:
SARS-CoV-2, Serology, Mathematical
modelling, Sero-reversiondeghi).
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2 C. Manisty et al. / EBioMedicine 65 (2021) 103259mild infection, anti-S1 serology alone may underestimate incident infections. The mechanisms that underpin
faster clearance and lower rates of sustained anti-S1 production may impact on the longevity of humoral
immunity.
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Detection of antibodies to SARS-CoV-2 is key to establishing the
prevalence of infection in the population, and hence tracking theprogress of the pandemic, and may be used to diagnose past infection
in individual patients. Moreover, antibody to envelope spike protein
may contribute to protective immunity [14]. Interpretation of
cross-sectional serology is critically dependent on understanding
the dynamics of the antibody response, and how this might vary
for different viral target antigens, in different assays and between
individuals.
Numerous studies have shown that individuals with a confirmed
polymerase chain reaction (PCR) diagnosis of SARS-CoV-2 develop
IgM, IgA and IgG against the spike protein S1 domain and nucleocap-
sid protein (NP) within 2 weeks of symptom onset, which remain
detectable following initial viral clearance [57]. Early data suggest
antibody levels correlate with disease severity [8, 9]. Antibody
responses to other human coronaviruses decay over time with regu-
lar reinfection events, which has caused concern that SARS-CoV-2
immunity following natural infection may be short-lived, leading to
risk of re-infection and making the possibility for achieving herd
immunity through natural infection unrealistic [1012]. The data for
SARS-COV-2 remains conflicting, with some longitudinal serological
studies suggesting rapid antibody decline, while others have much
greater persistence among peer reviewed literature [3, 1319] and
pre-prints [2022]. These vary by cohort (hospital, symptomatic
only, PCR positive, community), assay (quality-assured, antigen tar-
get), sampling granularity and follow-up period.
We present a detailed temporal analysis of circulating antibody
using two widely used semi-quantitative commercial assays to detect
either anti-S1 or anti-NP in a cohort of hospital health care workers in
a prospective longitudinal multi-centre cohort study with high fre-
quency serial sampling over 1621 weeks during the first epidemic
wave in London, UK. We assessed concordance between assays and
the determinants of inter-individual heterogeneity in antibody
responses by testing associations with clinical and demographic vari-
ables. Finally, we applied mathematical modelling to infer the funda-
mental mechanisms that may underpin changes to antibody levels
over time.
2. Methods
2.1 Study design and participants
The study was approved by a UK Research Ethics Committee
(South Central - Oxford A Research Ethics Committee, reference 20/
SC/0149). The details of participant screening, study design, sample
collection, and sample processing are previously published and regis-
tered on ClinicalTrials.gov, NCT04318314 [23]. Briefly, hospital
healthcare workers (HCWs) self-declared fit to attend work were
recruited to an observational cohort study consisting of question-
naires and biological sample collection at baseline and over 16
weekly-follow-up visits. Those who were unable to attend follow-up
visits were consulted remotely to enable capture of information
regarding possible exposures and symptoms. The baseline question-
naire included demographic data, medical history and exposures,
alongside detailed information regarding the nature and timing of
self-reported symptoms over the preceding 3 months [23]. Follow-
up weekly questionnaires included data on new symptoms and
changes to occupational and community risk factors, or results of
tests conducted outside of the study. Symptoms were classified as
follows: ‘case-defining’ (fever, new dry cough or a new loss of taste
C. Manisty et al. / EBioMedicine 65 (2021) 103259 3or smell; which have been shown to predict COVID-19 positivity with
high specificity), ‘non-specific (symptoms other than case-defining
symptoms), or asymptomatic (no symptoms reported throughout the
study period or in the three preceding months).
An initial cohort of 400 HCWs was recruited from St Bartholo-
mew’s Hospital, London, UK in the week of lockdown in the United
Kingdom (between 23rd and 31st March 2020); Cohort 1. Recruit-
ment was subsequently extended to include additional participants
from multiple sites between 27th April 2020 and 7th May 2020
(Cohort 2). This included St Bartholomew’s Hospital (n =101), NHS
Nightingale Hospital (n =10), and the Royal Free NHS Hospital Foun-
dation Trust (n=220). Data collection therefore extended over 21
weeks from baseline recruitment of Cohort 1 (the day of UK lock-
down) to completion of 16-week follow-up of Cohort 2. Towards the
end of the study period for Cohort 2 (follow-up weeks 1215) follow-
ing the decline in community infection rates, the frequency of blood
sampling was reduced to twice per month rather than weekly, in
order to improve tolerability to participants.
2.2 Procedures
RNA stabilizing swabs for molecular testing for SARS-CoV-2 were
acquired at baseline and weekly. RT-PCR was performed on nasopha-
ryngeal swabs using Roche cobas SARS-CoV-2 test for the ORF1A and
E genes. SARS-CoV-2 antibody testing was performed in a single labo-
ratory at Public Health England on all available serum samples from
baseline and follow-up visits using two commercial assays according
to manufacturers’ protocols. These were the Euroimmun anti-SARS-
CoV-2 enzyme-linked immunosorbent assay (ELISA) (IgG) targeting
IgG specific for the SARS-CoV-2 S1 antigen, and the Roche Elecsys
Anti-SARS-CoV-2 electrochemiluminescence immunoassay (ECLIA)
that detects antibodies (including IgG) directed against the SARS-
CoV-2 nucleocapsid protein (NP) [2427].
The Euroimmun ELISA was performed using a Stratec Gemini
automated microplate processor as previously described [28]. Raw
optical density (OD) readings were adjusted by calculating the ratio
of the OD of the control or participant sample divided by the OD of
the assay calibrator. A ratio 1.1 was used as the threshold for a posi-
tive result as per manufacturer’s instructions [1]. A ratio of 11 was
used as the upper threshold of the dynamic range, as the assay satu-
rated above this point. The Roche ECLIA was performed using the
Roche cobas e801 immunoassay analyser analyzer [24]. Results are
expressed as a cut-off index (COI), calculated by the analyser software
as the electrochemiluminescence signal obtained from the patient
sample divided by the lot-specific cut-off value [2]. A COI1 was
used as the threshold for a positive result as per manufacturer’s
instructions. Across their dynamic range, the semi-quantitative indi-
ces of both assays approximate to a linear relationship with antibody
levels (Supplementary Fig. 1). We have previously reported quantita-
tion of pseudovirus neutralising antibody (nAb) titres in 70 seroposi-
tive HCW from this cohort at 1618 weeks of follow up. Briefly,
lentiviral vectors pseudotyped with SARS-CoV-2 spike protein,
encoding firefly luciferase were produced in HEK-293 T cells and
used to infect Huh7 cells in the presence of serial dilutions of serum
as previously described [29].
2.3 Mechanistic mathematical modelling of antibody production
Circulating antibody levels are determined by the balance
between rates of production and clearance. We represented antibody
production by a simplified discrete mechanistic model captured by
Eq. (1), with time indexed to calendar weeks from initiation of UK
lockdown (as described for the survival analyses). We incorporated a
production rate (AbPr) and an antibody turnover (clearance rate, r).
Antibody production was simplified to two phases, an initial high
rate (AbPr1) followed by a switch to a lower rate (AbPr2), after a timet_stop. Since the assay units of antibody concentration are arbitrary
and are not comparable between assays, the value of AbPr 1 is also
arbitrary, and serves only to scale the model output to the scale of
the data. AbPr2 is expressed as a proportion of AbPr1. The rate of
clearance r can be directly calculated from the half-life, which was
allowed to vary between 1 week and 4 weeks (the latter equivalent
to the known turnover rate of free IgG). An important emerging fea-
ture of the model is that the time to plateau (peak) is determined
only by the clearance rate (Supplementary Fig. 2), and not by the rate
of production AbPr1. Furthermore, any subsequent fall from the peak
must reflect a corresponding decrease in AbPr. Hence the model
assumption that AbPr2<-AbPr1.
Eq. (1): Abt = Abt-1 + AbPr  Abt-1 * (1  e-rt), where t is time in
weeks, AbPr = AbPr1 for 1 < t < t_stop or AbPr2 for t_stop < t <
t_end; and AbPr2<AbPr1, and r = log(2)/half_life.
The levels of anti-S1 or anti-NP antibody in blood were compared
to the model, over a range of the parameters (AbPr1, AbPr2 as a pro-
portion of AbPr1, r and t_stop) by calculating the root mean square
distance between data and model output, and the parameter set with
the minimum distance was selected. In our primary analysis, we
restricted mathematical modelling to seropositive participants with
8 antibody data points (N=92 for anti-S1, N=86 for anti-NP, Supple-
mentary Fig. 3). In sensitivity analysis, we further restricted the
modelling to seroconverters in whom the first (baseline) sample was
negative.2.4 Statistical analysis
In descriptive analyses, Spearman’s rank correlation coefficients
were calculated for all paired assay values across the study period.
Univariable associations of demographics, symptoms and exposures
with serostatus (seropositivity by one or both antibody assays at any
timepoint) were assessed using logistic regression. Univariable and
multivariable associations of characteristics (including age, sex, eth-
nicity and case-defining symptom status) with peak antibody levels
were also quantified using linear regression for anti-N IgG/IgM and
anti-S1 IgG.
We also performed univariable and multivariable survival analy-
ses to assess whether participant characteristics (including age, sex,
ethnicity, case-defining symptom status and peak anti-S1) were asso-
ciated with time to sero-reversion for the anti-S1 assay. For this anal-
ysis, we included all participants who seroconverted on the anti-S1
assay at any point during follow-up. We assumed synchronous onset
of infection for these individuals by indexing the start time for the
survival analysis as the first week of Cohort 1 study enrolment (the
week of UK lockdown). Anti-S1 sero-reversion was defined as a nega-
tive test in the last assay performed during follow-up for each partici-
pant. Participants who sero-reverted exited the survival analysis on
the first week where a negative test (following an earlier positive
test) was recorded; those who did not sero-revert were censored on
the week of their last available anti-S1 serology result. Analyses were
conducted in R (version 3.6.3) and Stata Statistical Software version
16 (College Station, TX, USA).
Derived parameters from the mathematical models for the two
serology assays were compared by Mann-Whitney tests.2.5 Role of funding source
The funders had no role in study design, data collection, data anal-
ysis, data interpretation, or writing of the report. The corresponding
author had full access to all the data in the study and had final
responsibility for the decision to submit for publication.
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3.1 Study population
The study population has previously been published [23] and are
summarised in Supplementary Table 1. Briefly, this comprised 731
HCWs (median age 35 IQR 28 years, 33.0% male). Fourteen withdrew
(two with no samples obtained). Average weekly attendance was
61% with median 10 (IQR 6) visits per participant. 20.2% were doctors,
31.2% were nurses, 27.5% were allied healthcare professionals, 21.1%
were others including administrative and clerical. 22.6% worked in
an intensive care unit or emergency department setting. Co-morbid-
ities were relatively low (18.1% smokers, 12.6% BMI>30kg/m2, 10.7%
with asthma, 7.3% with hypertension, 2.1% with diabetes mellitus,
1.2% with rheumatological disease, 0.8% with cancer). 62.5% of partic-
ipants were white, 37.5% non-white with 5.6% of black ethnicity), and
47.6% reported a mean household size of 3 people. Exposure at
baseline to contacts with confirmed COVID-19 was high (42.7% to
patients, 29.5% to colleagues, and 1.1% to household members with
confirmed COVID-19) and 25.6% were exposed to aerosol generating
procedures.3.2 Seroconversion to SARS-CoV-2
In cohort 1 (recruited from 23rd March; day of UK lockdown), 28/
396 (7.1%) had a positive nasal PCR at baseline, with rates falling rap-
idly in the subsequent four weeks (Fig. 1) [30]. In cohort 2 (recruited
from 27th April, 5 weeks after UK lockdown and study start) 3/331
(0.9%) had positive nasal PCR swabs at their first study visit. There
were no positive PCR swabs across either cohort by 6 weeks after UK
lockdown (after 1st May 2020). The cumulative PCR positivity rate
was 6.6% (48/729).
Serology testing used both assays on all subjects at all timepoints
giving a total of 12,990 tests and median of 10 paired assays per indi-
vidual (Supplementary Fig. 3). Baseline seropositivity (by either
assay) in cohort 1 was 22/399 (5.5%), rising to 17.8% by study comple-
tion and 82/330 (25%) rising to 26.1% for cohort 2 (which started 5
weeks later). Overall, 157 of 729 (21.5%) had at least one seropositive
result. Of these, 137 (87%) had a seropositive result in both assays.
Consistent with the lack of nasal swab PCR detection of incident
infection by 6 weeks after UK lockdown, 98% of cumulative serocon-
versions were evident by 7 weeks after lockdown. Therefore, weFig. 1. Longitudinal infection with SARS-COV-2 over 21 weeks across 731 healthcare
workers.
Results from testing for SARS-CoV-2 by cohort showing weekly PCR percentage
positivity (weekly results, 95% CI) and seropositivity (cumulative percentage using
combined anti-S1 IgG and anti-NP IgM/IgG, standard error).reasoned that all incident infections in this study population occurred
in a narrow time window, centred around the week of UK lockdown,
during which recruitment of cohort 1 was initiated. As a result, the
aggregate data from the two cohorts provide a maximum follow up
of 21 weeks. Of the 48 participants in whom incident infection was
detected by a positive nasal swab PCR at any time point, 44 had sub-
sequent blood tests of which 42/44 (95.4%) became seropositive in at
least one assay. Subsequent anti-S1 seropositivity at any timepoint
was lower following a positive PCR result than anti-NP seropositivity
(86.4% versus 93.2%, respectively), although the time interval to sero-
conversion was faster (median 2.5 versus 3.0 weeks). Across all sam-
ples, binary outcomes at the manufacturers’ predefined thresholds
for each assay were concordant in 96.9% (6276/6476 samples), but
this reduced to 82.7% (953/1153) concordance in those samples
where at least one of the two assays were positive.
Of participants who were seropositive at any timepoint, 43.9%
reported case-definition symptoms during the study, 24.8% non-case
definition symptoms and 31.2% were completely asymptomatic. Only
two study participants were hospitalised, neither required ventila-
tory support or died. In univariable analysis, there was no association
between age or sex and seropositivity, but risk was higher in partici-
pants of Black ethnicity (odds ratio 2.61 [1.36, 4.98], p= 0.004,
Supplementary Fig. 4). Risk of infection could not be explained by
baseline co-morbidities or clinical roles, although HCWs based in ICU
had lower rates than others (OR 0.52 [0.30, 0.90], p=0.02). Reported
exposure to household members (baseline plus follow-up) with
COVID-19 was the strongest association with infection (OR 11.36
[2.27, 56.87], p=0.003). In contrast, reported exposure to SARS-CoV-2
positive patients or colleagues did not influence infection rates.
3.3 Longitudinal serology to SARS-CoV-2
Peak antibody measurements were highly variable between sero-
positive individuals across the cohort (coefficient of variation 77.89%
for anti-NP and 54.09% for anti-S1, Fig. 2). Despite infections being
mild, 7.7% participants had values at the threshold upper limit in the
Euroimmun anti-S1 assay. We extended our previous exploration of
associations with peak antibody measurements in subset of the
cohort [29] to the full cohort of seropositive participants (Supple-
mentary Tables 13). In multivariable analyses, there was a modest
positive association of increasing age with peak anti-S1 antibody
measurements (beta coefficient per year increase 0.05; 95% CI 0.01 to
0.09; p= 0.021), but not with anti-NP (beta coefficient 0.50; 95% CI
-0.22 to 1.2; p= 0.2). Black, Asian and minority ethnic groups were
associated with higher peak anti-NP responses (beta coefficient
22; 95% CI 4.9 to 39; p= 0.012), with a weaker association for peak
anti-S1 (beta coefficient 1.0; 95% CI 0.04 to 2.0; p= 0.058). We found
no association of peak antibody measurements with sex, or case-
defining symptom status.
Peak antibody measurements using the two assays correlated
(r= 0.57, p<0.001) (Supplementary Fig. 5). The correlation between
ranked antibody indices stratified by time interval from the start of
the study, revealed a shift from more highly ranked anti-S1 antibod-
ies in the first 6 weeks to more highly ranked anti-NP antibodies in
the last 8 weeks (Supplementary Fig. 6a), and the ratio of anti-S1:
anti-NP antibody measurements trended downwards over time
(Supplementary Fig. 6b). This analysis was consistent with different
temporal profiles in circulating antibody levels to these two targets.
Accordingly, among seropositive participants, time ordered aggregate
data for each assay showed anti-S1 antibody indices to reach a peak
and then fall more rapidly than the anti-NP antibody indices (Fig. 2).
By the end of the study 31/143 (21.7%) with positive Euroimmun
anti-S1 serology had reverted to negative, in comparison to 6/150
(4%) of those with positive Roche anti-NP serology.
We compared previously reported neutralising antibody (nAb)
titres in all seroconverters who attended for an additional blood
Fig. 2. Longitudinal antibody responses across all timepoints in participants seropositive at any timepoint
Individual participant data (left) and time ordered aggregate data (right) for Euroimmun anti-S1 antibody assay (N=145) (ab) and Roche combined anti-NP antibody assay
(N=150) (cd) showing the heterogeneity in antibody responses between individuals and the differences in antibody kinetics between assays, with an earlier peak and decline in
anti-S1 compared with anti-NP antibodies.
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S1 and anti-NP assay measurements in the present study in 54/70
participants for whom we had data from within two weeks of nAb
measurements. The inhibitory concentration (IC)50 titres showed
significant correlation to ranked anti-S1 antibody indices (r= 0.57,
p<0.0001) but not to anti-NP antibody indices at near-contemporary
time points (Fig. 3).
In univariable and multivariable survival analyses among partici-
pants who had a positive anti-S1 assay, higher peak anti-S1 responses
were associated with longer time to sero-reversion (hazard ratio 0.42
per unit increase when adjusted for age, sex, ethnicity and case-
defining symptom status; 95% CI 0.30 to 0.58; p<0.001; Supplemen-
tary Table 4). Age, sex, ethnicity and presence/absence of case-defin-
ing symptoms were not associated with time to sero-reversion.3.4 Mathematical modelling of kinetics of circulating anti-S1 and anti-
NP antibodies
We sought to obtain further insight into these underlying pro-
cesses by fitting a mathematical model to the antibody data. We first
fitted the model to the median of all the data for all individuals who
were seropositive at any time point, assuming approximately syn-
chronous infections coincident with the peak epidemic transmission
at the start of the study. The best fit models for the anti-S1 and anti-
NP data were clearly distinct. The inferred rate of clearance of S1 anti-
bodies was faster than that of NP antibodies, and the switch to alower antibody production rate occurred sooner and reduced by a
greater extent (Fig. 4ab).
We noted that individual antibody response profiles were hetero-
geneous in magnitude and dynamics (Fig. 2a). We therefore repeated
our analysis for each subject individually (Supplementary Fig. 6), and
derived the model parameters (Fig. 4ce). As anticipated, the best fit
model parameters across the cohort were highly heterogeneous.
However, clear differences could be observed between the anti-S1
and anti-NP antibody responses, reflecting the same hierarchy as we
observed when fitting the median antibody data. Thus, anti-S1 anti-
bodies have a shorter half-life (median 2.5 weeks, 95% CI 2-3) than
anti-NP antibodies (median 4 weeks, 95% CI 3-4). Production
switches to a lower rate more quickly (median 8 weeks, 95% CI 7-8
versus 13 weeks, 95% CI 13-14), and to a relatively lower level
(median 0.35, 95% CI 0.2-0.5 versus 0.5, 95% CI 0.05-0.5) with anti-S1
than with anti-NP antibodies, respectively. In general, there appeared
to be greater inter-individual heterogeneity in the best fit model
parameters for the Euroimmun anti-S1 antibody profiles than for the
Roche anti-NP antibody profiles (Fig. 4c-e). There were no strong
associations between model parameters (half-life of antibody clear-
ance, time to lower production rate and level of reduction) for either
assay with age, sex, ethnicity or symptoms.
In order to exclude the potential confounding effects of capturing
individuals only after antibody production was well established, we
repeated the analysis using only those who were seronegative at the
first available timepoint. The results were qualitatively the same for
this smaller sub-group (Supplementary Fig. 8).
Fig. 3. Correlation of anti-S1 and anti-NP antibody measurements with neutralising antibody titres at 1618 weeks.
Comparison of neutralising antibody (nAb) titres represented as 50% inhibitory concentrations (IC) with Euroimmun anti-S1 levels (a) and Roche anti-NP levels (b) in 54 partici-
pants with nAb measurements and near-contemporaneous (§2 weeks) Euroimmun and Roche serology. R and p values by Spearman rank correlations.
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We report a detailed time series analysis of circulating antibodies
to SARS-CoV-2 S1 and NP proteins following asymptomatic or pauci-
symptomatic infection, using two widely adopted commercial assays.
Antibody measurements were highly heterogeneous between sero-
positive individuals, however both assays show initial high sensitivity
for incident (even asymptomatic) infections following PCR detection
of virus on nasal swabs. These results are consistent with previous
evaluations of these tests in general [24, 25, 31], and alternative
assays targeting healthcare workers [32, 33]. Peak antibody index
measurements in each assay were significantly correlated, suggesting
both antigenic targets were similarly immunogenic. By 1621 weeks
after the peak of the epidemic wave in London, more than one in five
individuals who had developed positive serology to the virus spike
protein had sero-reverted by the Euroimmun anti-S1 assay. In con-
trast, reduction in Roche anti-NP measurements to subthreshold lev-
els was evident in less than one in twenty. These findings have
potentially important implications. First, it reveals that epidemiologi-
cal seroprevalence surveys may be biased by antibody decay over
this time horizon and may substantially underestimate incident
infections. Second, given that anti-S1 antibodies correlate with pro-
tective neutralising antibodies, the extent of the reduction in circulat-
ing levels of anti-S1 suggests that antibody-mediated protective
immunity in some individuals may be short-lived following asymp-
tomatic or pauci-symptomatic infection.
Semi-quantitative antibody measurements over the initial five
months following infection revealed differential kinetics for the two
assays. Anti-S1 antibodies reached peak levels before anti-NP anti-
bodies, but also showed a more rapid decline. It is interesting to spec-
ulate whether differential profiles of antibody assays can be exploited
to estimate the time of infection. We used mathematical modelling to
evaluate the determinants of the kinetic profiles and showed that the
differential time to peak antibody level is dependent on differential
clearance rates. Our model is consistent with a median half-life of 4
weeks for anti-NP antibodies consistent with long established esti-
mates for circulating IgG. The median half-life of anti-S1 antibodies
was significantly less, at 2.5 weeks. The subsequent fall in antibody
levels reveals a transition in antibody production to a lower level.
Our model estimated that this transition occurred at a median of 8
weeks for anti-S1 antibodies compared to a median of 14 weeks for
anti-NP antibodies. Finally, we sought to derive the relative rate of
antibody production after the transition. For both antibodies, this
reduced to at least 50% of antibody production rates before thetransition, but a substantial proportion of individuals exhibited sig-
nificantly greater reduction of anti-S1 antibody production. The com-
bination of lower antibody production rate and the natural clearance
of antibody resulted in levels falling below the detection threshold of
the assay in a significant proportion of the study cohort. In multivari-
able analysis, only peak anti‑S1 measurements were associated with
shorter time to anti-S1 sero-reversion.
The durability of antibodies to specific antigenic targets is highly
variable after different viral infections and the factors which deter-
mine these are poorly understood. Several hypotheses merit investi-
gation in future work. If the surface exposed domains of the SARS-
CoV-2 spike protein have greater propensity to form immune com-
plexes, increased rates of antibody clearance via immune complex
formation [34] may contribute to the shorter half-life of anti-S1 anti-
bodies. The transition to lower levels of antibody production may
represent the switch from antibody production from short lived plas-
mablasts to long lived plasma cells [35]. Importantly, immune com-
plexes are also known to regulate antibody production via inhibitory
Fc receptors on plasma cells [36]. Therefore, immune complex forma-
tion may also contribute to lower levels of anti-S1 antibody produc-
tion after the transition. Alternatively, there may be differences in
the relative contribution of short-lived extrafollicular memory B cells
versus long-lived plasma cells to the antibody responses against
these two antigens. We found a stronger T cell response at 1618
weeks to whole NP than whole spike antigen in this cohort [29];
future studies should test whether NP-specific T follicular helper cells
are better equipped to support an efficient germinal centre reaction
resulting in more long-lived plasma cells for NP than spike protein. In
addition, the better durability of anti-NP antibodies could relate to
differences in maintenance of their cognate antigen, for example on
follicular dendritic cells. Interestingly, N-antigenaemia has been
described [37]. How this might contribute to the longevity of anti-
body responses also merits consideration.
A key strength of our study is that the start at the time of first epi-
demic peak in London, UK, allowed the time of incident infection to
be estimated accurately (69.0% of cohort 1 recruited prior to serocon-
version) and the data were not confounded by prior exposures or
vaccine trials. In addition, the focus on asymptomatic and pauci-
symptomatic infection is representative of the vast majority of inci-
dent infections. Our finding that almost one in three were completely
free from symptoms despite detailed weekly contemporaneous data
collection to reduce recall bias is consistent with other estimates of
rates of asymptomatic infection pending peer review [21]. Serology
was assessed weekly with a median of 10 samples per participant
Fig. 4. Mathematical modelling of kinetics of circulating anti-S1 and anti-NP antibodies.
Model fit to aggregate (median) data from all seropositive participants for anti-S1 (N=92) (a) and anti-NP (N=86) (b) assays. Best fit model parameters for individual seropositive
participants for half-life of antibody clearance (c), time to transition point of lower antibody production (d) and relative reduction in antibody production following this transition
point (e). Horizontal lines (ce) showmedian and interquartile range. (P values are provided for comparison of model parameters by Mann-Whiney tests).
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performed, provide to our knowledge the most granular longitudinal
data currently available at this scale.
Previous reports of the longevity of circulating antibodies to SARS-
CoV-2 vary. Direct comparisons are undermined by the use of differ-
ent assays targeting distinct antigens, differences in study population
demographics, severity of illness, sampling frequency and duration of
follow up. Two themes have emerged. First, that there is a detectable
rate of reversion of seropositive individuals to becoming seronegative
over 3 to 6 months, consistent with our findings [3, 19, 22]. Some
reports, in preprint, have sought to predict the time to sero-reversion
with multilevel models to estimate the decay rate [20, 38]. Our find-
ings extend these analyses significantly by combining unprecedented
high frequency sampling and mathematical modelling to provide
dynamic estimates of production and clearance rates that determine
the overall levels of circulating antibody. Second, there are frequent
reports of an association between the clinical severity of infection
with magnitude of initial antibody responses and the longevity of cir-
culating antibody titres [15]. Whether, this explains recent studies
that show sustained levels in hospitalised patients over 3 to 6 months
[2, 39] will require further evaluation with detailed time series com-
parison of patients with and without severe disease. Our analysis
revealed no association between sero-reversion rates and symptoms,
but a limitation of our analysis is that the time of incident infection
was inferred in seropositive participants for whom we did not iden-
tify the infection by PCR.
Our study has other important limitations. Our time series analy-
sis was limited to individual semiquantitative assays for each anti-
genic target. Direct comparison of antibody levels was not possibledue to differences in dynamic range of these assays and their co-lin-
earity. Moreover, these assays did not provide any differential assess-
ment of antibody subclasses, which may exhibit differential kinetics.
Differences in isotype inclusion may also influence the modelling, but
exclusion of IgM in the Euroimmun anti-S1 assay does not explain
the faster clearance of these antibodies. At present, results from any
single assay may not be generalisable and will require further inde-
pendent validation with different assays for each antibody. The sig-
nificant correlation between near-contemporary Euroimmun anti-S1
measurements and functional pseudovirus nAb titres increased confi-
dence in our assessment of anti-S1 levels, and is in line with data
using live virus micro-neutralisation [40]. Alternative antibody assays
for the receptor binding domain within S1 have reported higher cor-
relation coefficients [41]. However, anti-S1 measurements may not
explain all humoral neutralising activity. In addition, emerging data
on T cell reactivity to SARS-CoV-2 highlights the potential role of cel-
lular immunity [16, 29, 42]. Therefore, the Euroimmun anti-S1 meas-
urements are not likely to provide a comprehensive measure of
protective immunity following natural infection. Nonetheless, our
data highlight the value of kinetic profiling of anti-S1 antibody
responses to the prevailing S antigen-based global vaccination pro-
gramme currently underway. Our study population may not be gen-
eralisable to all. Instead, it is representative of a workforce with likely
high exposure, and low risk of severe COVID-19. Cohort 1 may have
underestimated rates of infection because we were not able to recruit
those who were in self-isolation at the peak of transmission, whilst
cohort 2 may have overestimated rates of infection due to volunteer
bias seeking testing [43]. We do not expect either of these to con-
found our key findings. The sample size limited stratification of inter-
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Finally, our follow up duration of 21 weeks was derived from infer-
ring the time of incident infection in cohort 2 during the short inter-
val between the rapid evolution of the epidemic wave in London and
instigation the national lockdown which abruptly reduced transmis-
sion. Sensitivity testing using only participant data for whom the
time of seroconversion was known did not affect the derived parame-
ters for antibody production and clearance rates.
We conclude that asymptomatic and pauci-symptomatic infection
with SARS-CoV-2 elicits antibody responses to spike protein and to
nuclear protein antigens in the vast majority, but with heterogeneity
and differential temporal profiles. Anti-S1 antibodies measured by
the Euroimmun assay have a shorter half-life, transition from high to
lower levels of antibody production earlier and exhibit a greater
reduction in antibody production rate, compared to anti-NP antibod-
ies measured by the Roche assay. The important consequences of this
are that, used alone, anti-S1 assays may underestimate past infection
with implications for the application of this test for individual patient
care and population level epidemiological surveys. The mechanisms
that determine differential rates of antibody production and clear-
ance may impact on the longevity of protective humoral immunity to
SARS-CoV-2.
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